# GHK-Cu References: The Primary-Source Literature, Cited and Linked

> GHK-Cu references and primary sources — Pickart 1973, Mulder 1994, Leyden 2002, Miller 2006, Pyo 2007, Campbell 2012, Park 2022, He 2024, Czyrski 2024, and the supporting peer-reviewed corpus.

_Eyebrow: § 06 · REFERENCES_

## GHK-Cu References: The Primary-Source Literature

Every quantitative claim on this site cites a paper in this index. Studies span 1973 to 2024 and include foundational mechanism work, dermatology trials, hair-follicle assays, wound-healing trials, and recent fibrosis and liposomal-permeation papers.

## About this index

This GHK-Cu references index lists every peer-reviewed source cited on the site, numbered to match the inline [N] markers across /, /research, /dosage, /hair, and /faq. The corpus is weighted toward Pickart and co-authors — the dominant author group in foundational GHK-Cu biology — and includes independent groups (Mulder, Leyden, Miller, Pyo, Campbell, Park, He, Czyrski, Pai) for clinical, dermal-papilla, lung, fibrosis, and formulation work. Where DOIs exist they are listed; PMC and PubMed URLs are linked for direct full-text access where available.

## Citation balance note

The GHK-Cu corpus has a documented author-concentration in the work of Loren Pickart (Skin Biology, Inc.), who has authored or co-authored the 1973 Nature New Biology isolation paper, multiple BioMed Research International and IJMS reviews, and the Connectivity Map gene-expression integration work. This site cites that corpus because it is the corpus — but balances it deliberately with independent groups: Mulder (1994) for the diabetic-ulcer RCT, Leyden (2002) for the photoaging facial-cream trial, Miller (2006) for the CO2-laser study, Pyo (2007) for the dermal-papilla hair work, Campbell (2012) for the COPD emphysema gene-signature paper, Park (2022) for the mouse cigarette-smoke COPD model, He (2024) for the myofibroblast fibrosis paper, Czyrski (2024) for the liposomal-permeation work, and Pai (2017) for the consolidated topical anti-wrinkle review.

## References

[1] Pickart L, Thaler MM. A tripeptide in human serum which prolongs the survival of normal liver cells and stimulates the growth of hepatoma cells. Nature New Biology. 1973;243(124):85-87. — doi:10.1038/newbio243085a0 · PMID:4351778 · https://pubmed.ncbi.nlm.nih.gov/4351778/

[2] Pickart L, Vasquez-Soltero JM, Margolina A. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. BioMed Research International. 2015;2015:648108. — doi:10.1155/2015/648108 · https://pmc.ncbi.nlm.nih.gov/articles/PMC4508379/

[3] Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. International Journal of Molecular Sciences. 2018;19(7):1987. — doi:10.3390/ijms19071987 · PMID:29986520 · https://pmc.ncbi.nlm.nih.gov/articles/PMC6073405/

[4] Pickart L, Vasquez-Soltero JM, Margolina A. The Effect of the Human Peptide GHK on Gene Expression Relevant to Nervous System Function and Cognitive Decline. Brain Sciences. 2017;7(2):20. — doi:10.3390/brainsci7020020 · PMID:28212278 · https://pmc.ncbi.nlm.nih.gov/articles/PMC5332963/

[5] Leyden J, Stephens T, Finkey M, Appa Y, Barkovic S. Skin Care Benefits of Copper Peptide Containing Facial Cream. American Academy of Dermatology Annual Meeting Proceedings. 2002. — https://pmc.ncbi.nlm.nih.gov/articles/PMC4508379/

[6] Pickart L, Margolina A. Skin Regenerative and Anti-Cancer Actions of Copper Peptides. Cosmetics. 2018;5(2):29. — doi:10.3390/cosmetics5020029 · https://www.mdpi.com/2079-9284/5/2/29

[7] Mulder GD, Patt LM, Sanders L, Rosenstock J, Altman MI, Hanley ME, Duncan GW. Enhanced healing of ulcers in patients with diabetes by topical treatment with glycyl-L-histidyl-L-lysine copper. Wound Repair and Regeneration. 1994;2(4):259-269. — doi:10.1046/j.1524-475X.1994.20410.x · PMID:17147652 · https://onlinelibrary.wiley.com/doi/10.1046/j.1524-475X.1994.20410.x

[8] Pyo HK, Yoo HG, Won CH, Lee SH, Kang YJ, Eun HC, Cho KH, Kim KH. Effect of Tripeptide-Copper Complexes on the Proliferation of Human Dermal Papilla Cells. Biological & Pharmaceutical Bulletin. 2007;30(4):834-838. — doi:10.1248/bpb.30.834 · PMID:17409522 · https://pubmed.ncbi.nlm.nih.gov/17409522/

[9] He J, et al. The naturally occurring peptide GHK reverses age-related fibrosis by modulating myofibroblast function. Aging Pathobiology and Therapeutics. 2024;6(4). — doi:10.31491/APT.2024.12.158 · https://pmc.ncbi.nlm.nih.gov/articles/PMC12352503/

[10] Pickart L, Vasquez-Soltero JM, Margolina A. The Human Tripeptide GHK-Cu in Prevention of Oxidative Stress and Degenerative Conditions of Aging: Implications for Cognitive Health. Oxidative Medicine and Cellular Longevity. 2012;2012:324832. — doi:10.1155/2012/324832 · PMID:22666519 · https://onlinelibrary.wiley.com/doi/10.1155/2012/324832

[11] Pai V, Bhandari P, Shukla P. Topically applied GHK as an anti-wrinkle peptide. BioImpacts. 2017;7(4). — doi:10.15171/bi.2017.30 · https://bi.tbzmed.ac.ir/Inpress/bi-30071.pdf

[12] Campbell JD, McDonough JE, Zeskind JE, Hackett TL, Pechkovsky DV, et al. A gene expression signature of emphysema-related lung destruction and its reversal by the tripeptide GHK. Genome Medicine. 2012;4(8):67. — doi:10.1186/gm367 · PMID:22937864 · https://pmc.ncbi.nlm.nih.gov/articles/PMC4064320/

[13] Park JR, Lee H, Kim SI, Yang SR. Glycyl-L-histidyl-L-lysine-Cu2+ attenuates cigarette smoke-induced pulmonary emphysema and inflammation by reducing oxidative stress pathway. Frontiers in Molecular Biosciences. 2022;9:929185. — doi:10.3389/fmolb.2022.929185 · https://pmc.ncbi.nlm.nih.gov/articles/PMC9354777/

[14] Czyrski A, Resztak M, Hermann TW, Kus K, Glowka FK. Are We Ready to Measure Skin Permeation of Modern Antiaging GHK-Cu Tripeptide Encapsulated in Liposomes? Pharmaceutics. 2024;16(12):1526. — doi:10.3390/pharmaceutics16121526 · https://pmc.ncbi.nlm.nih.gov/articles/PMC11721469/

---

A horizontal-timeline reading of the GHK-Cu literature from Pickart 1973 to the 2024 fibrosis and liposomal-permeation work — eleven milestones scanned, copper-binding events marked separately from downstream effects, and signed by no clinic and no vendor.